Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of YHP2511 and YHP2511A in Healthy Volunteers
NCT07470125Phase 1Completed
- Sponsor
- Yuhan
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YHP2511 in hypercholesterolemia (2 arms), sponsored by Yuhan. Primary endpoints: Area under the plasma drug concentration-time curve at 72 hours and Maximum plasma concentration at 72 hours. Started Jun 2026; status: completed.
02
Drugs
YHP2511
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07470125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470125.